[Research progress of pathogenesis and treatment of persistent airflow limitation asthma].

Persistent airflow limitation (PAL) asthma is a clinical phenotype of asthma, which has more severe symptoms, more difficult to control and worse prognosis than ordinary asthma. At present, there is still a lack of full understanding of the intrinsic mechanism of PAL asthma. It is mainly believed that the pathogenesis of PAL asthma is related to airway inflammation, airway remodeling and lung parenchyma remodeling. At present, the guidelines at home and abroad still recommend the combination of ICS, long-acting β2-agonist (LABA), long-acting muscarinic antagonist (LAMA) and other drugs as needed for PAL asthma, but the efficacy is limited. This article reviews the research progress in the pathogenesis and treatment of PAL asthma.